摘要
目的探讨紫杉醇联合顺铂与多西他赛联合卡铂治疗晚期卵巢癌的疗效及安全性差异。方法将62例晚期卵巢癌患者随机分组,实验组患者应用多西他赛联合卡铂治疗,对照组患者给予紫杉醇联合顺铂治疗。比较2组患者治疗效果、无进展生存期、2年病死率、不良反应发生率和MMP-2、VEGF水平差异。结果实验组疾病控制率为80.65%,较对照组的77.43%无统计学差异(P>0.05)。实验组无进展生存期为(490.24±42.09)d,明显高于对照组(411.75±39.56)d(P<0.05);实验组2年病死率为35.49%,同对照组的45.16%无明显差异(P>0.05)。实验组不良反应发生率为29.04%,与对照组的32.25%无统计学差异(P>0.05)。实验组治疗12周和24周MMP-2、VEGF水平均低于对照组(P<0.05)。结论紫杉醇联合顺铂与多西他赛联合卡铂均可有效治疗晚期卵巢癌,安全性均较高,其中多西他赛联合卡铂可延长患者无进展生存期,改善MMP-2、VEGF水平,值得推广应用。
Objective To investigate the efficacy and safety of paclitaxel combined with cisplatin and docetaxel combined with carboplatin in the treatment of advanced ovarian cancer.Methods 62 patients with advanced ovarian cancer were randomly divided into 2 groups.The experimental group was treated with docetaxel combined with carboplatin,while the control group was treated with paclitaxel combined with cisplatin.The therapeutic effect,progression-free survival,2-year mortality,incidence of adverse reactions and levels of MMP-2 and VEGF were compared between the 2 groups.Results The disease control rate of the experimental group was 80.65%,which was not significantly different from the control group 77.43%(P>0.05);The progression-free survival of the experimental group(490.24±42.09)d was significantly higher than that of the control group(411.75±39.56)d(P<0.05).There was no significant difference between the experimental group’s 2-year mortality rate of 35.49%and the control group,45.16%(P>0.05);The incidence of adverse reactions was 29.04%in the experimental group and32.25%in the control group(P>0.05).The levels of MMP-2 and VEGF in the experimental group were lower than those of the control group at 12 and 24 weeks(P<0.05).Conclusion Paclitaxel combined with cisplatin and docetaxel combined with carboplatin can effectively treat advanced ovarian cancer with high safety.Docetaxel combined with carboplatin can prolong progression-free survival and improve MMP-2 and VEGF levels.It is worth promoting.
作者
周惠人
张雅欣
李玉静
ZHOU Huiren;ZHANG Yaxin;LI Yujing(Luoyang Oriental Hospital,Luoyang,471003)
出处
《实用癌症杂志》
2019年第11期1888-1890,共3页
The Practical Journal of Cancer
关键词
紫杉醇联合顺铂
多西他赛联合卡铂
晚期卵巢癌
疗效
安全性
Paclitaxel combined with cisplatin
Docetaxel combined with carboplatin
Advanced ovarian cancer
Efficacy
Safety
